Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus: a Randomise Prospective Study

NCT05339217 is registered in ClinicalTrials.gov with Liu Tian as lead sponsor.

NCT NCT05339217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05339217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus: a Randomise Prospective Study
Lead sponsor
Liu Tian
Phase
Phase 3
Overall status
Unknown status
Start date
February 7, 2023
Completion date
July 1, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus